Mesoblast Receives A$3.7 Million From the Australian Government for Research and Development Activities
April 06 2017 - 6:00AM
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it
has received A$3.7 million from the Australian Government for
Research & Development (R&D) activities conducted during
the 2016 financial year. The funds were provided to Mesoblast under
the Government's R&D Tax Incentive Program, which is designed
to support industry innovation.
About MesoblastMesoblast Limited
(Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative
cell-based medicines. The Company has leveraged its proprietary
technology platform, which is based on specialized cells known as
mesenchymal lineage adult stem cells, to establish a broad
portfolio of late-stage product candidates. Mesoblast’s allogeneic,
‘off-the-shelf’ cell product candidates target advanced stages of
diseases with high, unmet medical needs including cardiovascular
conditions, orthopedic disorders, immunologic and inflammatory
disorders and oncologic/hematologic conditions.
Forward-Looking StatementsThis press release
includes forward-looking statements that relate to future events or
our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, levels of activity, performance or achievements to differ
materially from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. We make such forward-looking statements pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Forward-looking
statements should not be read as a guarantee of future performance
or results, and actual results may differ from the results
anticipated in these forward-looking statements, and the
differences may be material and adverse. You should read this press
release together with our risk factors, in our most recently filed
reports with the SEC or on our website. Uncertainties
and risks that may cause Mesoblast's actual results, performance or
achievements to be materially different from those which may be
expressed or implied by such statements, and accordingly, you
should not place undue reliance on these forward-looking
statements. We do not undertake any obligations to publicly update
or revise any forward-looking statements, whether as a result of
new information, future developments or otherwise.
For further information, please contact:
CORPORATE COMMUNICATIONS
Julie Meldrum
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
INVESTOR RELATIONS
Schond Greenway
T: +1 212 880 2060
E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2023 to Apr 2024